Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes

INTRODUCTION: We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD). METHODS: Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020. RESULTS: 574 patients were included; mean age 71 years, 81% males, with a high...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabouret, Pierre François, Dib, Jean-Claude, Ecarnot, Fiona, Banach, Maciej, Lellouche, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696963/
http://dx.doi.org/10.5114/aoms/173511
Descripción
Sumario:INTRODUCTION: We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD). METHODS: Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020. RESULTS: 574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean lipid-density lipoprotein cholesterol was 85 mg/dl, mean glycated hemoglobin HbA(1c) 7.1%, mean triglycerides 148 mg/dl; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA. CONCLUSIONS: In this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.

Ejemplares similares